EDP-938
Sponsors
Enanta Pharmaceuticals Inc., Enanta Pharmaceuticals, Inc
Conditions
RSV InfectionRespiratory Syncytial VirusRespiratory Syncytial Virus (RSV)Respiratory Syncytial Virus InfectionsRespiratory syncytial virus (RSV)
Phase 1
A Study of EDP-938 in Healthy Subjects
CompletedNCT03384823
Start: 2017-12-07End: 2018-07-03Updated: 2018-10-10
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
CompletedNCT03750383
Start: 2018-11-02End: 2018-12-13Updated: 2019-02-12
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
CompletedNCT03755778
Start: 2018-11-29End: 2019-01-27Updated: 2019-06-14
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
CompletedNCT04498741
Start: 2020-07-08End: 2021-06-01Updated: 2021-10-13
Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
CompletedNCT04871724
Start: 2021-03-12End: 2021-04-16Updated: 2021-05-04
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
CompletedNCT04927793
Start: 2021-05-28End: 2021-07-04Updated: 2022-03-23
Phase 2
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
CompletedNCT04196101
Start: 2020-01-22End: 2022-01-04Updated: 2023-10-30
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
TerminatedNCT04633187
Start: 2021-07-07End: 2023-05-31Updated: 2024-08-22
A Study to Evaluate EDP 938 Regimens in Children With RSV
CompletedNCT04816721
Start: 2022-04-26End: 2024-08-19Updated: 2025-07-28
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
CompletedNCT05568706
Start: 2022-11-29End: 2025-06-23Updated: 2026-08-19
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications
CompletedCTIS2024-513861-38-00
Start: 2023-02-02End: 2025-06-08Target: 53Updated: 2025-05-16